Oxford Biomedica Confirms Total Voting Rights at 120.9 Million Shares
I'm LongbridgeAI, I can summarize articles.Oxford Biomedica has confirmed its total voting rights at 120,920,518 ordinary shares, all with voting rights, as of April 30, 2026. This routine governance disclosure aids in regulatory compliance and transparency for shareholders. The latest analyst rating for OXB stock is a Buy with a price target of £1170.00, although Spark's AI Analyst rates it as Neutral due to weak financial performance and bearish technicals. Oxford Biomedica specializes in cell and gene therapy, serving global clients with advanced manufacturing capabilities.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from Oxford BioMedica ( (GB:OXB) ).
Oxford Biomedica has confirmed that its issued share capital at the close of business on 30 April 2026 comprises 120,920,518 ordinary shares, all carrying voting rights and with none held in treasury. This figure establishes the company’s current total voting rights and serves as the reference denominator for investors assessing whether they must disclose changes in their holdings under UK transparency rules.
The update is a routine governance disclosure but provides clarity to shareholders and the market on Oxford Biomedica’s capital base following any recent corporate actions. By formalising the voting rights count, the company supports regulatory compliance and maintains transparency for stakeholders monitoring ownership thresholds in the FTSE 250-listed CDMO.
The most recent analyst rating on (GB:OXB) stock is a Buy with a £1170.00 price target. To see the full list of analyst forecasts on Oxford BioMedica stock, see the GB:OXB Stock Forecast page.
Spark’s Take on OXB Stock
According to Spark, TipRanks’ AI Analyst, OXB is a Neutral.
The score is held back primarily by weak financial performance (still loss-making with negative operating/free cash flow despite improvement) and bearish technicals (price below key moving averages with negative MACD and weak RSI). Valuation provides limited support due to negative earnings and no dividend yield data.
To see Spark’s full report on OXB stock, click here.
More about Oxford BioMedica
Oxford Biomedica (OXB) is a UK-headquartered contract development and manufacturing organisation specialising in cell and gene therapy. The company focuses on viral vector development and manufacturing, including lentiviral, AAV and adenoviral platforms, serving global pharmaceutical and biotech clients from facilities in the UK, France and the U.S.
With three decades of expertise, OXB provides services spanning early-stage development through to commercial production, underpinned by advanced technologies such as its TetraVecta lentiviral system and dual-plasmid AAV platform. Its quality systems and regulatory capabilities position the group as a key CDMO player in the fast-growing cell and gene therapy market.
Average Trading Volume: 330,287
Technical Sentiment Signal: Buy
Current Market Cap: £708.5M